Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes
Shots:
- Lilly to acquire Hydra- in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists
- The focus of the acquisition is to develop treatments for chronic pain and understand TRP pathway in pain signaling- further initiate clinical trials
- Hydra’s Transient Receptor Potential (TRP) channel program consists of group of non-selective cation channels indicated for the treatment of pain- inflammation and hypertension
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
